Denmark to restrict Ozempic, other GLP-1 drugs, to treat type 2 diabetes
Demand for Novo Nordisk’s diabetes drug Ozempic has soared as many people have started using the diabetes drug for its weight-loss effects. A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. Reuters
Denmark will start putting patients suffering from type 2 diabetes on cheaper drugs before prescribing so-called GLP-1 drugs such as Novo Nordisk’s (NOVOb.CO) Ozempic, the Danish Medicines Agency said on Wednesday.
In 2023, 50% of new patients suffering from type 2 diabetes began treatment with a reimbursed GLP-1 drug without trying a cheaper alternative first, the Medicines Agency said.
Demand for Novo Nordisk’s diabetes drug Ozempic has soared as many people have started using the diabetes drug for its weight-loss effects.
25.12°C Kathmandu
